Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Fri, 04.10.2024
Relief Therapeutics Holding SA
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
GENEVA (OCT. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseas [ … ]
Thu, 03.10.2024
Redcare Pharmacy N.V.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
Q3 total Group sales up 21% year over year to EUR 574M and year to date 34% to EUR 1.7bn; non-Rx sales growth 20% year over year to EUR 383M and also 20% year to date to EUR 1.2bn.
Active cus [ … ]
Thu, 03.10.2024
ABIVAX
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s na [ … ]
Thu, 03.10.2024
Redcare Pharmacy N.V.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
Sevenum, the Netherlands, 3 October 2024. The Management Board of Redcare Pharmacy has decided to intensify marketing investments for its e-Rx business in Ger [ … ]
Thu, 03.10.2024
J.P. Morgan SE
3 October 2024
Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.
Springer Nature AG & Co. KGaA
Pre-stabilisation period announcement
J. P. Morgan SE (contact: Ashish Jhajharia; telephone: +44 0 207 134 2983) hereby gives notice that the Stabilisation [ … ]
Thu, 03.10.2024
Edison Investment Research Limited
London, UK, 3 Oktober 2024
Edison issues report on Henderson Opportunities Trust (HOT)
Edison issues report on Henderson Opportunities Trust (LSE: HOT).
With a focus on long-term growth, Henderson Opportunities Trust (HOT) seeks investment opportunities across the breadth of the UK market. This includes a strong bias towards smaller and ea [ … ]
Thu, 03.10.2024
Lehman Brothers UK Capital Funding II LP
NOTICE TO THE HOLDERS OF:
EUR 250,000,000 EURO FIXED RATE GUARANTEED NON-VOTING, NON-CUMULATIVE PERPETUAL PREFERRED SECURITIES ("LP II Securities")
ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING II LP ("LP II")
ISIN: XS0229269856
LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP II SECURITIES
THIS NOTI [ … ]
Thu, 03.10.2024
H2APEX Group SCA
H2APEX Successfully Completes Construction of a Hydrogen Refueling Station for One of Europe’s Largest Hydrogen Bus Fleets
Municipal transport company rebus from Rostock County relies on the expertise of hydrogen specialist H2APEX – Long-term supply of green hydrogen secured.
Rostock, Güstrow, October 2, 2024 – Sustainable, environmentally fri [ … ]
Thu, 03.10.2024
Lehman Brothers UK Capital Funding III LP
NOTICE TO THE HOLDERS OF:
EUR 500,000,000 FIXED/FLOATING RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP III ECAPS")
ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING III LP ("LP III")
ISIN: XS0243852562
LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP III ECAPS
THIS NOTICE CONTAINS IMPORTANT [ … ]
Thu, 03.10.2024
BRAIN Biotech AG
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Superv [ … ]